Vericel Corp. | Ownership
Companies that own Vericel Corp.
Consonance Capital Management LP
3,608,092
8.44%
503,500
2.35%
06/30/2018
SSgA Funds Management, Inc.
2,583,906
6.05%
2,537,224
0%
06/30/2018
BlackRock Fund Advisors
2,389,392
5.59%
1,341,941
0%
06/30/2018
RTW Investments LP
2,217,916
5.19%
150,000
1.55%
06/30/2018
Archon Capital Management LLC
1,945,877
4.55%
-445,685
12.96%
06/30/2018
The Vanguard Group, Inc.
1,926,210
4.51%
521,865
0%
06/30/2018
Marshall Wace North America LP
1,315,550
3.08%
1,315,550
0.09%
06/30/2018
Eastern Capital Ltd.
1,298,081
3.04%
-1,677,192
5.18%
03/09/2018
Driehaus Capital Management LLC
847,491
1.98%
548,474
0.21%
06/30/2018
Millennium Management LLC
794,367
1.86%
174,631
0.01%
06/30/2018
| Address |
64 Sidney Street
Cambridge Massachusetts 02139
United States
|
|
Employees
|
- |
| Website |
http://www.vcel.com |
| Updated |
07/08/2019 |
| Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies to repair and regenerate damaged tissues and organs to normal structure and function. Its product portfolio include MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. |
